Peptidylarginine Deiminase 2 in Host Immunity: Current Insights and Perspectives

Frontiers in Immunology

Zhenyu Wu¹  Wenlu Ouyang¹  Patrick Li²  Yuzi Tian³  Hasan B. Alam⁴  Jessie Wai-Yan Ho⁴  Yongqing Li⁵ 

[1] Department of Infectious Diseases, Xiangya 2nd Hospital, Central South University, Changsha, China;Department of Internal Medicine, New York University (NYU) Langone Health, New York, NY, United States;Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China;Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States;Department of Surgery, University of Michigan Hospital, Ann Arbor, MI, United States;

关键词: PAD2;    autoimmune diseases;    sepsis;    NETosis;    pyroptosis;   

DOI  :  10.3389/fimmu.2021.761946

来源: DOAJ

【 摘 要 】

Peptidylarginine deiminases (PADs) are a group of enzymes that catalyze post-translational modifications of proteins by converting arginine residues into citrullines. Among the five members of the PAD family, PAD2 and PAD4 are the most frequently studied because of their abundant expression in immune cells. An increasing number of studies have identified PAD2 as an essential factor in the pathogenesis of many diseases. The successes of preclinical research targeting PAD2 highlights the therapeutic potential of PAD2 inhibition, particularly in sepsis and autoimmune diseases. However, the underlying mechanisms by which PAD2 mediates host immunity remain largely unknown. In this review, we will discuss the role of PAD2 in different types of cell death signaling pathways and the related immune disorders contrasted with functions of PAD4, providing novel therapeutic strategies for PAD2-associated pathology.

【 授权许可】

Unknown